What changed
What changedOn November 17, 2026, the Boston Scientific board of directors approved the 2027 annual bonus plan and two long-term stock incentive programs for management. Simultaneously, the company announced that David S. Wichmann will become lead independent director effective January 1, 2027.

What changedBoston Scientific reported financial results for the third quarter of 2026, which ended September 30. The company's net sales for this period were $5,138 million.

What changedBoston Scientific said Arthur C. Butcher will leave his role as executive vice president and group president, MedSurg and Asia Pacific, and will become a senior advisor through February 26, 2027 with a base salary of $780,000. Joe Fitzgerald is promoted to executive vice president and chief operating officer with a base salary of $1,050,000, a target bonus of 110% and a planned equity grant of $7 million.

Company history
October 2026
BOSTON SCIENTIFIC CORP: 12 recorded developments from 3 official sources in 2026-10.
- 2026-09-23: On September 21, 2026, Arthur C. Butcher informed Boston Scientific Corporation (the “Company”) that he has decided to retire from his role as Executive Vice President and Group President, MedSurg and Asia Pacific effective as of January 1, 2027. Source
- 2026-09-23: Mr. Butcher is expected to remain with the Company as a senior advisor from such time through February 26, 2027 (such date, or any earlier date, the “Retirement Date”). Source
- 2026-09-23: As a senior advisor, Mr. Butcher will receive a base salary at his current annual base salary of $780,000, prorated through the Retirement Date. Source
- 2026-09-23: Pursuant to the Retirement Agreement, Mr. Butcher will be entitled to payments and benefits that are materially consistent with those he is entitled to under the Company’s Executive Retirement Plan, 2026 Annual Bonus Plan and Long-Term Incentive Program and equity awards granted thereund Source
- 2026-10-07: There are no arrangements or understandings between Mr. Bickel and any other person pursuant to which Mr. Bickel was selected as an officer, there are no family relationships between Mr. Bickel and any director or other officer of the Company, and Mr. Bickel does not have any direct or i Source
- 2026-10-07: Item 8.01 Other Events. A copy of the Company’s press release dated October 7, 2026, announcing the events described under Item 5.02 above is included in this filing as Exhibit 99.1. Source
- 2026-10-07: On October 7, 2026, Boston Scientific Corporation announced that Joe Fitzgerald, who currently serves as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer of the Company, effective as of January 1, 2027 Source
- 2026-10-07: Mr. Fitzgerald, age 63, joined the Company in 1990, and has held a variety of management positions in the Company's Cardiovascular business; in his current position, which he has held since May 2022, Mr. Fitzgerald oversees development and commercialization of advanced heart therapies fo Source
- 2026-10-07: Mr. Fitzgerald will have continued eligibility to participate in the Company's Annual Bonus Plan, with an incentive target percentage equal to 110% of his annual base salary. Source
- 2026-10-07: Mr. Fitzgerald will have continued eligibility to participate in the Company's Deferred Bonus Plan, under which he is able to elect to defer up to 75% of the annual bonus awarded to him for each applicable year. Source
- 2026-10-07: Ms. Woodworth will continue serving in her current position as Senior Vice President, Global Controller and Chief Accounting Officer, which she has held since January 2024, until March 1, 2027, at which time Ms. Woodworth will no longer serve as the Company’s Chief Accounting Officer. Source
- 2026-10-28: On October 28, 2026, Boston Scientific Corporation issued a press release announcing financial results for the third quarter ended September 30, 2026. Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Expectations and reality
Open
The company expects to deliver common stock shares in settlement of satisfied Performance Share Units no later than March 15, 2030.
Said November 17, 2026 · Period named: March 15, 2030 · Source · Our article
Not yet checked against later reports.
The company established an annual bonus plan for the performance period of January 1 to December 31, 2027.
Said November 17, 2026 · Period named: January 1 - December 31 · Source · Our article
Not yet checked against later reports.
The Company approved the 2027 Annual Bonus Plan for the performance year January 1, 2027 through December 31, 2027.
Said November 17, 2026 · Period named: January 1, 2027 through December 31, 2027 · Source · Our article
Not yet checked against later reports.
Shares of common stock will be delivered no later than March 15, 2030, in settlement of performance share units if performance and eligibility criteria are met.
Said November 17, 2026 · Period named: March 15, 2030 · Source · Our article
Not yet checked against later reports.
Boston Scientific estimates full year 2026 adjusted EPS, excluding certain charges (credits), to be $3.16 to $3.18.
Said October 28, 2026 · Source · Our article
Not yet checked against later reports.
Boston Scientific estimates full year 2026 net sales growth versus the prior year period to be approximately 4.25 percent on a reported basis and approximately 3.75 percent on an organic basis.
Said October 28, 2026 · Period named: full year 2026 · Source · Our article
Not yet checked against later reports.
Show all (11)
Boston Scientific Corporation estimates Q4 2026 reported net sales growth/(decline) to be between (3.0)% and (1.0)%, and full year 2026 reported growth to be ~4.25%.
Said October 28, 2026 · Period named: Q4 and FY 2026 · Source · Our article
Not yet checked against later reports.
Boston Scientific Corporation estimates Q4 2026 operational net sales growth/(decline) to be between (3.0)% and (1.0)%, and full year 2026 operational growth to be ~3.75%.
Said October 28, 2026 · Period named: Q4 and FY 2026 · Source · Our article
Not yet checked against later reports.
Boston Scientific estimates fourth quarter 2026 net sales to decline versus the prior year period by approximately (3.0) to (1.0) percent on a reported and organic basis.
Said October 28, 2026 · Period named: fourth quarter of 2026 · Source · Our article
Not yet checked against later reports.
Boston Scientific Corporation estimates Q4 2026 organic net sales growth/(decline) to be between (3.0)% and (1.0)%, and full year 2026 organic growth to be ~3.75%.
Said October 28, 2026 · Period named: Q4 and FY 2026 · Source · Our article
Not yet checked against later reports.
Boston Scientific estimates fourth quarter 2026 adjusted EPS, excluding certain charges (credits), to be $0.77 to $0.79.
Said October 28, 2026 · Period named: Fourth Quarter 2026 · Source · Our article
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Changes in risk factors
The 10-Q filed November 2, 2026 compared with the 10-Q filed August 3, 2026: risk paragraphs that were added or dropped, quoted as filed. SEC
Added (24)
- Net increase (decrease) in commercial paper | 1,003 | | | (196)
- On September 11, 2026, we entered into a definitive agreement to acquire 100 percent of Jiangsu TingSN Technology Co., Ltd (TingSN), a privately held medical device company headquartered in China, that develops and commercializes catheter-based medical technologies for cardiac and vascular interventions, including diagnostic intravascular and intracardiac ultrasound imaging solutions. The purchase price consists of an upfront cash payment of approximately $250 million and up to an additional $75 million in future payments upon achievement of commercialization and sales milestones. The…
- On October 2, 2026, we entered into an agreement with funds managed by Blackstone Life Sciences Advisors L.L.C. (Blackstone) to co-fund development activities for our VITALYST™ Temporary Percutaneous Transvalvular Circulatory Support System for the treatment of patients with acute myocardial infarction with cardiogenic shock (the Product). Under the agreement, we are eligible to receive up to $455 million from contract inception through regulatory approval of the Product in the United States, unless otherwise terminated, based on qualifying development costs incurred. As there is substantive…
Dropped (8)
- Fair value of contingent consideration | 100 | | | 98 | | | 38
- | $ | 220 | | | $ | 255 | | | $ | — | | | $ | 475 | | | $ | 1,092 | | | $ | 181 | | | $ | — | | | $ | 1,273
- | $ | — | | | $ | 1,198 | | | $ | 257 | | | $ | 1,455 | | | $ | — | | | $ | 1,308 | | | $ | 392 | | | $ | 1,700
Found by comparing the two reports paragraph by paragraph, without AI. A new or dropped risk is not by itself a sign of trouble.
Governance events
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
| Date | Event | Filing |
|---|
| November 17, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
| October 7, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
| September 23, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
| September 8, 2026 | Material cybersecurity incident (8-K item 1.05) | 8-K |
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|
| BlackRock | 125,556,119 | $5,480,524,601 | -3.2% | Q3 2026 |
| State Street | 67,322,516 | $2,938,627,823 | -4.0% | Q3 2026 |
| Fidelity (FMR) | 40,115,549 | $1,751,043,728 | -12.2% | Q3 2026 |
| Geode Capital Management | 34,468,097 | $1,497,660,949 | +3.1% | Q3 2026 |
| D. E. Shaw & Co. | 21,245,733 | $927,376,246 | -16.5% | Q3 2026 |
| Wellington Management | 21,004,216 | $916,834,028 | +37.3% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 21,170,029 | $903,536,838 | — | Q2 2026 |
| Two Sigma Investments | 20,006,783 | $873,296,078 | +3.3% | Q3 2026 |
| Capital Research Global Investors | 17,241,496 | $752,597,850 | +21.6% | Q3 2026 |
| Citadel Advisors | 7,812,630 | $341,021,300 | +56.6% | Q3 2026 |
| Renaissance Technologies | 1,765,305 | $77,055,563 | -26.8% | Q3 2026 |
| Millennium Management | 1,121,537 | $27,130,090 | -79.4% | Q3 2026 |
| Bridgewater Associates | 437,208 | $19,084,129 | -1.1% | Q3 2026 |
| T. Rowe Price | 6,750,795 | $294,673 | -4.5% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.